Piper Sandler raised the firm’s price target on Regeneron to $1,166 from $1,000 and keeps an Overweight rating on the shares. The firm says its two new Eylea surveys are largely supportive of a bullish view of the overall franchise. Reported and projected share would seem to support Piper’s above-consensus Eylea HD estimates, the analyst tells investors in a research note. Piper says its overall franchise estimates remain meaningfully above consensus through 2025, and based on feedback, it remains confident in that setup. The analyst remains a buyer of the stock.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron exec Larosa sells 1,866 common shares
- Regeneron price target raised to $1,250 from $1,124 at UBS
- Jefferies healthcare analyst holds an analyst/industry conference call
- Regeneron price target lowered to $1,182 from $1,183 at Morgan Stanley
- Regeneron price target raised to $1,200 from $1,050 at Barclays